Vycor Medical, Inc. reported financial results for the year ended December 31, 2025, showing substantial growth in its neurosurgical division and important clinical validation for its therapeutic programs. The company's performance highlights the increasing global adoption of its medical technologies and the shifting landscape toward remote healthcare solutions.
The Vycor Medical division, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, saw revenues increase by 18% over 2024, reaching $1,796,070. Most of this growth came from international markets, reflecting successful execution of the company's global expansion strategy, though sales growth continued in the United States. This international growth contributed to the company's overall revenue of $1,863,400, representing a 17% increase over the previous year.
Clinical validation played a significant role in the company's 2025 performance. Seven new peer-reviewed studies were published on the VBAS system during the year, bringing the total published peer-reviewed clinical papers to 50, with an additional 14 other clinical papers. These studies originated from multiple countries including the United States, United Kingdom, Japan, and Mexico, demonstrating the system's global clinical acceptance. The research consistently highlighted clinical advantages including reduced brain tissue damage, improved patient outcomes, and reduced hospital stays.
For an overview of Vycor Medical's VBAS system, see https://www.vycormedical.com.
The company's operating performance showed marked improvement, with operating profit reaching $33,900 compared to an operating loss of $(9,145) in 2024. On a non-GAAP basis, which excludes non-cash depreciation and stock-based compensation, operating profit was $145,881 compared to $81,548 in 2024. Gross profit for 2025 was $1,498,295, an 11% increase over 2024, though the margin decreased to 83% from 89% due to validation, shipping, higher manufacturing costs of new production, and a higher international sales mix.
The NovaVision division, which remains in development, generated revenues of $67,330 for the year ended December 31, 2025, and achieved a 93% gross margin. A significant clinical study on NovaVision's NeuroEyeCoach was published during 2025, comparing results from using the program at home with using it in a clinic. The study concluded that both home-based and clinic-based patients showed meaningful improvements with no significant differences between the two settings in activities of daily living improvements. This validation of remote effectiveness aligns with global healthcare trends toward digital home-based therapies.
For information about NovaVision's vision rehabilitation therapies, visit https://www.novavision.com.
The company's financial results demonstrate the growing acceptance of minimally invasive neurosurgical technologies and the potential for digital therapeutic solutions in home settings. The international expansion of VBAS, supported by increasing clinical evidence across multiple countries, suggests broader global healthcare adoption of technologies that reduce tissue damage and improve patient recovery times. Similarly, the validation of home-based effectiveness for NeuroEyeCoach addresses a critical need in healthcare systems worldwide seeking to expand access to rehabilitation services through digital platforms.
These developments have implications for healthcare providers, patients, and investors. For neurosurgeons, the expanding clinical evidence base for VBAS provides additional confidence in adopting the technology for improved patient outcomes. For patients with visual impairments from stroke or brain injury, the validation of home-based therapy options could increase access to effective rehabilitation. From an investment perspective, the company's transition to operating profitability and successful international expansion indicates potential for sustainable growth in specialized medical technology markets.
The company's performance reflects broader trends in healthcare toward evidence-based medical devices and remote therapeutic solutions. As healthcare systems globally seek to improve outcomes while managing costs, technologies that demonstrate both clinical effectiveness and operational efficiency, whether in surgical settings or home-based rehabilitation, are likely to see increased adoption. The financial and clinical results reported by Vycor Medical provide concrete evidence of these trends materializing in real-world medical practice and patient care.
